Biotechnology
Medical
Biopharmaceutical

Alder BioPharmaceuticals

$11.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.45%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALDR and other stocks, options, ETFs, and crypto commission-free!

About

Alder BioPharmaceuticals, Inc. Common Stock, also called Alder BioPharmaceuticals, is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Read More Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Employees
202
Headquarters
Bothell, Washington
Founded
2004
Market Cap
920.70M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
962.77K
High Today
$11.23
Low Today
$10.92
Open Price
$11.10
Volume
248.46K
52 Week High
$20.87
52 Week Low
$9.44

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
2014 IPO

News

Yahoo FinanceMay 7

Here’s What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)

With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter.

75
Yahoo FinanceMay 6

Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials

Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate more than 50% of patients achieved rapid onset of migraine prevention with eptinezumab on Day 1 across four clinical trials BOTHELL, Wash., May 06, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new efficacy data highlighting consistency of early migraine prevention benefit across fou...

74
The Motley FoolMay 3

Alder BioPharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Call Transcript

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Q1 2019 Earnings Call May 2, 2019, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon and welcome to the Alder Biopharmaceuticals first quarter 2019 financial results conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's requ...

35

Earnings

-$1.73
-$1.42
-$1.11
-$0.80
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.